EcoDrugPlus

Cell Division Cycle 7

Ensembl ID : ENSPNAG00000028164
Gene Symbol: CDC7
3 Cross references
207 Possible Orthologues:

Cellular Tumor Antigen P53-Like

Ensembl ID : ENSPNAG00000017221
Gene Symbol: LOC108436226
2 Cross references
232 Possible Orthologues:

Checkpoint Kinase 1

Ensembl ID : ENSPNAG00000016155
Gene Symbol: CHEK1
3 Cross references
177 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSPNAG00000002789
Gene Symbol: CHEK2
3 Cross references
205 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSPNAG00000011557
Gene Symbol: CCKAR
4 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSPNAG00000005838
Gene Symbol: CCKBR
4 Cross references
131 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSPNAG00000015413
Gene Symbol: LOC108434752
3 Cross references
253 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSPNAG00000008158
Gene Symbol: LOC108412547
3 Cross references
258 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSPNAG00000016378
Gene Symbol: CETP
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSPNAG00000023269
Gene Symbol: CHRM1
3 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSPNAG00000018150
Gene Symbol: CHRM2
3 Cross references
185 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSPNAG00000027264
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).